+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 40Years - 75Years
All Genders
ID07612774

Randomized Comparison of Early Evolocumab Plus Standard Lipid Therapy Versus Standard Care in Acute Coronary Syndrome Using Serial Photon-Counting CT

Led by West China Hospital · Updated on 2026-10-07

232

Participants Needed

2

Research Sites

60 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effect of early treatment with evolocumab combined with standard lipid-lowering therapy compared to standard therapy alone in patients who have acute coronary syndrome ACS and have undergone successful percutaneous coronary intervention. This randomized, open-label study with blinded endpoint assessment uses advanced photon-counting coronary computed tomography angiography PCCT-CCTA to monitor coronary plaque changes over time. The goal is to see if intensive LDL cholesterol lowering with evolocumab can reduce plaque progression and to assess PCCT-CCTA as a tool for tracking atherosclerosis. Participants are randomly assigned to receive either evolocumab plus standard lipid-lowering therapy or standard-of-care lipid-lowering therapy alone. Both groups undergo PCCT-CCTA scans and laboratory tests at the start and at 52 weeks to measure changes in coronary plaque volume, stenosis severity, and high-risk plaque features. The study also tracks lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes during this 52-week treatment period. Participants commit to completing baseline tests within 7 days of enrollment and follow-up visits over 52 weeks. Researchers assess total atherosclerotic volume, stenosis severity especially at key coronary arteries, and plaque characteristics using imaging. Safety and clinical events are monitored throughout. The study duration extends up to the end date in 2029, with primary outcome assessment at one year, providing detailed data on the effects of early evolocumab treatment on coronary artery disease progression.

CONDITIONS

Brief Title

CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS

Research Team

X

Xiaoyu Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here